Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neonatal Clear all
Completed Phase 1Phase 2 Interventional Results available

Targeted Microbiome Transplant in Atopic Dermatitis

NCT03151148
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
TMT Lotion, Placebo Lotion
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Interventions
dupilumab, Topical emollient (moisturizer)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-050/NCNP-03, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 15 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Preventing Complications in Cleft Palate Repair With Antibiotics

NCT00760006
View directory record Official record
Conditions
Cleft Palates
Interventions
Unasyn, saline solution
Drug · Other
Lead sponsor
Joseph Losee
Other
Eligibility
3 Months to 18 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Not listed No phase listed Observational

STRIDE Biorepository

NCT02843347
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Blood draw
Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting No phase listed Observational

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

NCT05224778
View directory record Official record
Conditions
Congenital Myotonic Dystrophy, CDM
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 59 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting No phase listed Observational

InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

NCT05929976
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer, Microtia, Genetic Predisposition
Interventions
No intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
3 Years to 18 Years
Enrollment
4,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01839916
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
therapeutic allogeneic lymphocytes, laboratory biomarker analysis
Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

NCT03073733
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells, Mock injection
Biological · Other
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Irvine, California • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

NCT05405985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

NCT00701415
View directory record Official record
Conditions
Fabry Disease
Interventions
Agalsidase beta
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years to 18 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

NCT00134017
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Busulfan, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)

NCT00111384
View directory record Official record
Conditions
Neurofibromatosis Type 1, Legius Syndrome
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

Rasch-analysis of Clinical Severity in FSHD

NCT02766985
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Kansas City, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study

NCT00722943
View directory record Official record
Conditions
Premature Birth of Newborn
Interventions
Developmental Massage Therapy, no intervention
Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 14 Days
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07601425
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions
ATV-1601, Placebo
Drug
Lead sponsor
Atavistik Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

AMPED Outcomes Registry of Post-ED Pain Management

NCT01626235
View directory record Official record
Conditions
Soft Tissue Injuries, Gouty Arthritis, Fractures, Ureteral Colic, Dysmenorrhea
Interventions
Not listed
Lead sponsor
Radnor Registry Research, Inc
Industry
Eligibility
18 Years and older
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases

NCT00357435
View directory record Official record
Conditions
Corneal Dystrophies, Hereditary, Corneal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated No phase listed Observational

Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD

NCT00261989
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2011 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis

NCT01197417
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Intravenous Magnesium Sulfate, Normal Saline Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microcurrent Stimulation to Treat Macular Degeneration

NCT01790958
View directory record Official record
Conditions
Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Milk Warming on the Very Low Birth Weight Infant

NCT04282655
View directory record Official record
Conditions
Very Low Birth Weight Infant, Weight Gain, Feeding Disorder Neonatal
Interventions
Treatment Guardian Milk Warmer (Medela TM), Control
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Day to 30 Days
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

NCT03566043
View directory record Official record
Conditions
Mucopolysaccharidosis Type II (MPS II)
Interventions
RGX-121
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
4 Months to 5 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Oakland, California • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 10, 2026, 4:41 PM EDT